Table 1. Demographic and baseline characteristics of the patients.

	All (N = 261)	TACE (N = 197)	Sorafenib (N = 64)	P
Age	56 (20–83)*	58(20–84)*	54 (20–79)*	0.103
Sex (N)				0.094
Male	241	185	56
Female	20	12	8
BMI (kg/m2)	24(15–32)*	24 (15–32)*	23 (16–33)*	0.840
Cause of disease (N)				1.000
HBV	195	147	48
HCV	4	3	1
Negative	62	47	15
Child–Pugh class (N)				0.231
A	180	132	48
B	81	65	16
BCLC (N)
AB		62	13	0.081
B		75	26
C		60	25
Vascular invasion				0.114
No	176	138	38
Yes	85	59	26
Cirrhosis				0.984
Yes	196	148	48
No	65	49	16
MD (mm)	75 (42–187)*	74 (42–187)*	77 (48–175)*	0.821
Lesion number (N)				0.446
N = 1	113	93	20
N = 2	67	33	34
N = 3	13	3	10
N ≥ 4	68	68	0
Albumin (g/L)	35 (21–48)*	35 (22–44)*	34 (21–48)*	0.568
TBIL (μmol/L)	20 (5–52)*	20 (8–52)*	22 (5–37)*	0.812
Prothrombin time	14 (12–16)*	14 (12–15)*	14 (12–16)*	0.418
ALT (μmol/L)	38 (10–566)*	38 (15–566)*	39 (10–236)*	0.480
AFP (N)				0.125
< 25μg/mL	69	57	12
25–400 μg/mL	93	71	22
> 400 μg/mL	99	69	30

Abbreviations:* median (range) for data without normal distribution.

BCLC: Barcelona Clinic Liver Cancer; BMI: body mass index; HBV: hepatitis B virus; HCV: hepatitis C virus; MD: maximum diameter; TBIL: total bilirubin; ALT: alanine aminotransferase, AFP: alpha fetoprotein.